A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

RashNon-small-Cell Lung Cancer

Interventions

DRUG

ACZONE (dapsone) Gel, 5%

DRUG

Vehicle Control

Trial Locations (3)

Penn State Milton S. Hershey Medical Center, Hershey

Fox Chase Cancer Center, Philadelphia

Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago